AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11352777 — intervention group
Group type: COMPARATOR
Intervention: Hypoglycaemia and placebo
Number of subjects: 16
Study 11352777 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycaemia and caffeine
Number of subjects: 16
Study 9509071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure from 2000 h to 0200 h
Number of subjects: 10
Study 9509071 — intervention group
Group type: COMPARATOR
Intervention: Normal room lighting from 2000 h to 0200 h
Number of subjects: 10
Study 9509071 — intervention group
Group type: COMPARATOR
Intervention: Normal room lighting from 2000 h to 2400 h
Number of subjects: 10
Study 7522527 — intervention group
Group type: EXPERIMENTAL
Intervention: CABO (cisplatin, methotrexate, bleomycin, and vincristine)
Number of subjects: 382
Study 7522527 — intervention group
Group type: EXPERIMENTAL
Intervention: CF (cisplatin and 5-fluorouracil)
Number of subjects: 382
Study 7522527 — intervention group
Group type: COMPARATOR
Intervention: C (cisplatin)
Number of subjects: 382
Study 7522527 — intervention group
Group type: EXPERIMENTAL
Intervention: CABO
Number of subjects: 382
Study 7522527 — intervention group
Group type: EXPERIMENTAL
Intervention: CF
Number of subjects: 382
Study 7522527 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 382
Study 7522527 — intervention group
Group type: EXPERIMENTAL
Intervention: CABO and CF
Number of subjects: 382
Study 7522527 — intervention group
Group type: COMPARATOR
Intervention: CABO, CF, and C
Number of subjects: 382
Study 3257915 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (started 72 h before operation)
Number of subjects: 60
Study 3257915 — intervention group
Group type: COMPARATOR
Intervention: Control (no atenolol)
Number of subjects: 60
Study 30418256 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat
Number of subjects: 0
Study 30418256 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS
Number of subjects: 0
Study 29684501 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum rheology measures (G', G" and solids content)
Number of subjects: 15
Study 26654252 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Exercise Group (FEG - extrinsic and intrinsic foot muscles)
Number of subjects: 83
Study 26654252 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot and Hip Exercise Group (FHEG - abductor and lateral rotator muscles)
Number of subjects: 83
Study 26654252 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching Alone Exercise Group (SAEG)
Number of subjects: 83
Study 26654252 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 83
Study 25285767 — intervention group
Group type: EXPERIMENTAL
Intervention: Blanketrol II (Automatic control mode)
Number of subjects: 0
Study 25285767 — intervention group
Group type: EXPERIMENTAL
Intervention: Blanketrol III (Gradient mode)
Number of subjects: 0
Study 25285767 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 0
Study 22832329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol infusion (two concentrations)
Number of subjects: 24
Study 22832329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol infusion (highest dose level)
Number of subjects: 24
Study 22832329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20819318 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 1.25 mg (q.d. for infants, b.i.d. for children)
Number of subjects: 242
Study 20819318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 17934678 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive seminar training for practice nurses
Number of subjects: 629
Study 17934678 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 629
Study 17934678 — intervention group
Group type: COMPARATOR
Intervention: Routine asthma outcome measures (beta2-agonist prescription rate and number of oral steroid courses)
Number of subjects: 629
Study 17934678 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire data (Mini AQLQ and Asthma Control Questionnaire)
Number of subjects: 629
Study 15743537 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy extract capsules (2 capsules containing daidzin : genistin = 7.79 : 22.57 mg)
Number of subjects: 12
Study 15743537 — intervention group
Group type: COMPARATOR
Intervention: Soy beverage (prepared from 15 g of soy flour containing daidzin : genistin = 9.27 : 10.51 mg)
Number of subjects: 12
Study 15743537 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy extract capsules
Number of subjects: 12
Study 15743537 — intervention group
Group type: COMPARATOR
Intervention: Soy beverage
Number of subjects: 12
Study 10682229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 301
Study 10682229 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 301
Study 10682229 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life outcomes
Number of subjects: 301
Study 10682229 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic outcomes
Number of subjects: 301
Study 10682229 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional imaging outcomes
Number of subjects: 301
Study 9052446 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet supplemented with 30 g per day of L-arginine for 3 days before surgery
Number of subjects: 18
Study 9052446 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital diet (controls)
Number of subjects: 18
Study 7511242 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 76
Study 7511242 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum alpha-fetoprotein (AFP) measurement
Number of subjects: 76
Study 2868480 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 16
Study 2868480 — intervention group
Group type: EXPERIMENTAL
Intervention: procyclidine
Number of subjects: 16
Study 2868480 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 2893865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous penicillin (6 million units/day for 7 days)
Number of subjects: 42
Study 2893865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31749238 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexagliflozin 5 mg
Number of subjects: 292
Study 31749238 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexagliflozin 10 mg
Number of subjects: 292
Study 31749238 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexagliflozin 20 mg
Number of subjects: 292
Study 31749238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 31749238 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexagliflozin (all doses)
Number of subjects: 292
Study 31381171 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of alcohol (mean BrAC = 0.11%)
Number of subjects: 98
Study 31381171 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 98
Study 31381171 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of alcohol (mean BrAC = 0.04%)
Number of subjects: 98
Study 28969667 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP point-of-care test (POCT) to guide antibiotic prescribing
Number of subjects: 650
Study 28969667 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 650
Study 28969667 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP POCT
Number of subjects: 650
Study 24794584 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-tailored intervention
Number of subjects: 828
Study 24794584 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 828
Study 24231273 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspinous process device
Number of subjects: 159
Study 24231273 — intervention group
Group type: COMPARATOR
Intervention: Standard bony decompression
Number of subjects: 159
Study 22204615 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (2 mA, 20 mins)
Number of subjects: 0
Study 22204615 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (20 mins)
Number of subjects: 0
Study 22204615 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation followed by cognitive-behavioral group programme
Number of subjects: 0
Study 22204615 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation followed by cognitive-behavioral group programme
Number of subjects: 0
Study 19481728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental imagery sessions
Number of subjects: 68
Study 19481728 — intervention group
Group type: COMPARATOR
Intervention: Reading a book chapter describing cystoscopy (Control)
Number of subjects: 68
Study 16982287 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 79
Study 16982287 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 79
Study 16982287 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 79
Study 14982685 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion (300 mg) with behavioral counseling for 10 weeks
Number of subjects: 555
Study 14982685 — intervention group
Group type: COMPARATOR
Intervention: placebo with behavioral counseling
Number of subjects: 555
Study 11387607 — intervention group
Group type: EXPERIMENTAL
Intervention: Large burrs (burr/artery ratio of >0.7)
Number of subjects: 222
Study 11387607 — intervention group
Group type: COMPARATOR
Intervention: Small burrs (burr/artery ratio < or = 0.7)
Number of subjects: 222
Study 9000704 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 1008
Study 9000704 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 1008
Study 7683552 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuG-CSF 20 micrograms/kg/day
Number of subjects: 121
Study 7683552 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuG-CSF
Number of subjects: 121
Study 3325289 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 20
Study 3325289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31065120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and Misoprostol
Number of subjects: 60
Study 31065120 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol Alone
Number of subjects: 60
Study 28872196 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 183
Study 28872196 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 183
Study 26302441 — intervention group
Group type: EXPERIMENTAL
Intervention: LAI risperidone
Number of subjects: 95
Study 26302441 — intervention group
Group type: COMPARATOR
Intervention: Oral risperidone
Number of subjects: 95
Study 23792133 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally-centered, culturally-tailored lifestyle intervention delivered by trained AA community health workers (CHW) during 16 contacts
Number of subjects: 200
Study 23792133 — intervention group
Group type: COMPARATOR
Intervention: Approved diabetes educational mailings (control group)
Number of subjects: 200
Study 21431408 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS + HIPEC (cisplatin 120 mg and mitomycin C 30 mg in 6000 ml of normal saline at 43 ± 0.5°C for 60-90 min)
Number of subjects: 68
Study 21431408 — intervention group
Group type: COMPARATOR
Intervention: CRS alone
Number of subjects: 68
Study 21431408 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS + HIPEC
Number of subjects: 68
Study 18305083 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl 7.5% (HS)
Number of subjects: 62
Study 18305083 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl 0.9% 32 ml kg(‐1) (NS32)
Number of subjects: 62
Study 18305083 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (NS4)
Number of subjects: 62
Study 17140532 — intervention group
Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 217
Study 17140532 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv(TM)
Number of subjects: 217
Study 17140532 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary instruments
Number of subjects: 217
Study 17140532 — intervention group
Group type: COMPARATOR
Intervention: Operator effect
Number of subjects: 217
Study 12572334 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy
Number of subjects: 0
Study 12572334 — intervention group
Group type: COMPARATOR
Intervention: Surgical tracheostomy
Number of subjects: 0
Study 10606834 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg fosinopril (n=12 patients)
Number of subjects: 55
Study 10606834 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg enalapril (n=12 patients)
Number of subjects: 55
Study 10606834 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg fosinopril (n=16 patients)
Number of subjects: 55
Study 10606834 — intervention group
Group type: COMPARATOR
Intervention: 5 mg lisinopril (n=15 patients)
Number of subjects: 55
Study 10606834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinoprilat
Number of subjects: 55
Study 9105340 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized balance training
Number of subjects: 72
Study 9105340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 72
Study 9105340 — intervention group
Group type: COMPARATOR
Intervention: Educational group (Control)
Number of subjects: 72
Study 8240458 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg/day for 3 weeks
Number of subjects: 16
Study 8240458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8240458 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 16
Study 3513558 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.22 micron filterset (real filter)
Number of subjects: 70
Study 3513558 — intervention group
Group type: COMPARATOR
Intervention: Filter cartridge without a 0.22 micron membrane (blank filter)
Number of subjects: 70
Study 31933301 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the quit smoking project
Number of subjects: 626
Study 31933301 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving invitation to join the program
Number of subjects: 626
Study 31933301 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' willingness to participate in the program
Number of subjects: 626
Study 31933301 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and communication skills
Number of subjects: 626
Study 29390128 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard models to analyze cluster‐randomized trials
Number of subjects: 0
Study 29390128 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling for amount of time exposed to the intervention
Number of subjects: 0
Study 29390128 — intervention group
Group type: EXPERIMENTAL
Intervention: Analyzing subsets of workers with least mobility
Number of subjects: 0
Study 29390128 — intervention group
Group type: EXPERIMENTAL
Intervention: Reanalysis of previously conducted trial
Number of subjects: 0
Study 26961765 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient sleep (<10 hrs/day)
Number of subjects: 298
Study 26961765 — intervention group
Group type: COMPARATOR
Intervention: Sufficient sleep (≥10 hrs/day)
Number of subjects: 298
Study 25282563 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily emollient therapy applied at least once per day starting within 3 weeks of birth
Number of subjects: 124
Study 23144893 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 0
Study 23144893 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 21073605 — intervention group
Group type: EXPERIMENTAL
Intervention: OAB-M-F (metronidazole 500 mg bid for 5 days, followed by furazolidone 200 mg bid for 5 days)
Number of subjects: 310
Study 21073605 — intervention group
Group type: COMPARATOR
Intervention: OAC-P (clarithromycin 500 mg bid for 10 days, placebo)
Number of subjects: 310
Study 21073605 — intervention group
Group type: EXPERIMENTAL
Intervention: OAB-C-F (clarithromycin 500 mg bid for 5 days, followed by furazolidone 200 mg bid for 5 days)
Number of subjects: 310
Study 17713873 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sage extract (SE) in a hydrophilic ointment
Number of subjects: 40
Study 17713873 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone
Number of subjects: 40
Study 17713873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone
Number of subjects: 40
Study 17713873 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (placebo)
Number of subjects: 40
Study 15854934 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 818
Study 15854934 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 818
Study 12153334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (starting at 50 mg/day, increasing to 200 mg/day, and up to 600 mg/day if tolerated)
Number of subjects: 79
Study 12153334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 79
Study 9832659 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% diphenhydramine
Number of subjects: 30
Study 9832659 — intervention group
Group type: COMPARATOR
Intervention: 0.9% buffered lidocaine
Number of subjects: 30
Study 9832659 — intervention group
Group type: COMPARATOR
Intervention: 0.9% benzyl alcohol with epinephrine
Number of subjects: 30
Study 9832659 — intervention group
Group type: EXPERIMENTAL
Intervention: All anesthetics
Number of subjects: 30
Study 7977066 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum lipoprotein(a) levels
Number of subjects: 610
Study 7977066 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum homocyst(e)ine levels
Number of subjects: 610
Study 7977066 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with > or = 1 occluded vein graft
Number of subjects: 610
Study 7977066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of lipoprotein(a) levels
Number of subjects: 610
Study 7977066 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative serum lipoprotein(a) and homocyst(e)ine levels
Number of subjects: 610
Study 2521552 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled pirenzepine (70 micrograms)
Number of subjects: 0
Study 2521552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (7 micrograms)
Number of subjects: 0
Study 30457934 — intervention group
Group type: EXPERIMENTAL
Intervention: Early contact condition (2-week follow-up contact)
Number of subjects: 800
Study 30457934 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no early follow-up)
Number of subjects: 800
Study 28505360 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cefazolin (500 mg h-1)
Number of subjects: 20
Study 28505360 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus of cefazolin (2 g every 4 h)
Number of subjects: 20
Study 26931670 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-median consumption of milk
Number of subjects: 960
Study 26931670 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-median consumption of fruits and vegetables
Number of subjects: 960
Study 26931670 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate consumption of yogurts and cottage cheese
Number of subjects: 960
Study 26931670 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-median consumption of other cheeses
Number of subjects: 960
Study 26931670 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-median consumption of bread
Number of subjects: 960
Study 26931670 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest sodium intakes
Number of subjects: 960
Study 25005464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 gram orally 3 times daily for 3 months)
Number of subjects: 22
Study 25005464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 gram orally 3 times daily for 3 months)
Number of subjects: 22
Study 21334223 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 6 months
Number of subjects: 36
Study 20477776 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parent-based intervention (PBI) and brief motivational intervention (BMI)
Number of subjects: 1275
Study 20477776 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 1275
Study 20477776 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based intervention (PBI)
Number of subjects: 1275
Study 20477776 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control
Number of subjects: 1275
Study 16983692 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular water (via vaporizing humidifier)
Number of subjects: 10
Study 16983692 — intervention group
Group type: COMPARATOR
Intervention: Particulate water (via aerosol spray)
Number of subjects: 10
Study 16357661 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental physical therapy (PT) from birth until four months corrected age (CA), weekdays during the neonatal stay and on a needs- and problem-oriented basis thereafter.
Number of subjects: 72
Study 16357661 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (NT) group (no intervention).
Number of subjects: 72
Study 16357661 — intervention group
Group type: COMPARATOR
Intervention: Control group of infants born full term (n = 14).
Number of subjects: 72
Study 16357661 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental PT with high levels of parental compliance.
Number of subjects: 72
Study 12409172 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol or quetiapine
Number of subjects: 10
Study 12409172 — intervention group
Group type: COMPARATOR
Intervention: normal controls
Number of subjects: 10
Study 10776294 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation
Number of subjects: 2
Study 10776294 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visual stimulation)
Number of subjects: 2
Study 10500946 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg kg‐1 (Group M)
Number of subjects: 180
Study 10500946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms kg‐1 (Group F)
Number of subjects: 180